These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study. Andersen G; Hedermann G; Witting N; Duno M; Andersen H; Vissing J Brain; 2017 Sep; 140(9):2295-2305. PubMed ID: 29050397 [TBL] [Abstract][Full Text] [Related]
43. Sodium channel slow inactivation as a therapeutic target for myotonia congenita. Novak KR; Norman J; Mitchell JR; Pinter MJ; Rich MM Ann Neurol; 2015 Feb; 77(2):320-32. PubMed ID: 25515836 [TBL] [Abstract][Full Text] [Related]
44. [Effective treatment of paramyotonia congenita by mexiletene]. Nezu A; Yamashita S; Miyake S; Hayashi M; Iwamoto H No To Hattatsu; 1986 May; 18(3):236-7. PubMed ID: 3707771 [No Abstract] [Full Text] [Related]
45. Severity, type, and distribution of myotonic discharges are different in type 1 and type 2 myotonic dystrophy. Logigian EL; Ciafaloni E; Quinn LC; Dilek N; Pandya S; Moxley RT; Thornton CA Muscle Nerve; 2007 Apr; 35(4):479-85. PubMed ID: 17230537 [TBL] [Abstract][Full Text] [Related]
52. [Myotonia and muscular weakness corrected by exercise--clinical and EMG study apropos of a case]. Ruh D; Warter JM; Marescaux C; Malibary H; Jesel M Rev Electroencephalogr Neurophysiol Clin; 1982 Aug; 12(2):140-6. PubMed ID: 7134580 [No Abstract] [Full Text] [Related]
53. Calixmexitil: Calixarene-based Cluster of Mexiletine with Amplified Anti-myotonic Activity as A Novel Use-dependent Sodium Channel Blocker. Delnavaz Shahr A; Nasuhi Pur F Iran J Pharm Res; 2019; 18(3):1351-1357. PubMed ID: 32641945 [TBL] [Abstract][Full Text] [Related]
54. [Neuromuscular diseases as a cause of neonatal respiratory insufficiency]. Dinger J; Lorenz P Monatsschr Kinderheilkd; 1991 Oct; 139(10):692-4. PubMed ID: 1961209 [TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of mexiletine in non-dystrophic myotonias: A randomised, double-blind, placebo-controlled, cross-over study. Vicart S; Franques J; Bouhour F; Magot A; Péréon Y; Sacconi S; Nadaj-Pakleza A; Behin A; Zahr N; Hézode M; Fournier E; Payan C; Lacomblez L; Fontaine B Neuromuscul Disord; 2021 Nov; 31(11):1124-1135. PubMed ID: 34702654 [TBL] [Abstract][Full Text] [Related]
56. [Muscle weakness or rigidity due to hereditary ion channel diseases]. Links TP; van der Hoeven JH Ned Tijdschr Geneeskd; 2001 Feb; 145(6):249-51. PubMed ID: 11236369 [TBL] [Abstract][Full Text] [Related]
58. Phenotypic variability in myotonia congenita. Colding-Jørgensen E Muscle Nerve; 2005 Jul; 32(1):19-34. PubMed ID: 15786415 [TBL] [Abstract][Full Text] [Related]
59. Synthesis and in vitro sodium channel blocking activity evaluation of novel homochiral mexiletine analogs. Carocci A; Catalano A; Bruno C; Lentini G; Franchini C; De Bellis M; De Luca A; Conte Camerino D Chirality; 2010 Mar; 22(3):299-307. PubMed ID: 19544349 [TBL] [Abstract][Full Text] [Related]
60. [Electromyographic features of 3 forms of myotonia]. Luk'ianov MV; Chuchin MIu Zh Nevropatol Psikhiatr Im S S Korsakova; 1982; 82(11):37-44. PubMed ID: 7180301 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]